Repligen Corporation Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Waltham MA United States (1981)

Organization Overview

First Clinical Trial
2002
NCT00036244
First Marketed Drug
2022
eflapegrastim (Rolvedon)
First NDA Approval
2022
eflapegrastim (Rolvedon)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree